Inactive Total Small Business Set-Aside (FAR 19.5)

This is Amendment 03. The purpose of this amendment is to post responses to submitted questions via Attachment 09 Amend 3_RFQ_ 75N95023R00065 _Q&A. Please see Attachment 09 Amend 3_RFQ_ 75N95023R00065... This is Amendment 03. The purpose of this amendment is to post responses to submitted questions via Attachment 09 Amend 3_RFQ_ 75N95023R00065 _Q&A. Please see Attachment 09 Amend 3_RFQ_ 75N95023R00065 _Q&A. This is Amendment 02. The purpose of this amendment is to post responses to submitted questions via Attachment 08 Amend 2_RFQ_ 75N95023R00065 _Q&A. Please see Attachment 08 Amend 2_RFQ_ 75N95023R00065 _Q&A. This is Amendment 01. This Amendent is to replace Attachment 7 - EVALUATION CRITERIA with Attachment 7A - EVALUATION CRITERIA Regulatory Affairs. Please see Attachment 7A - EVALUATION CRITERIA Regulatory Affairs. The NIH is seeking senior-level, industry-experienced drug discovery and development consultants with expertise in small molecules and / or biologics to provide Regulatory Affairs Strategy and document development Consulting services to the following programs: • Regulatory Affairs consulting to support the NIH Blueprint Neurotherapeutics program [BPN]. • Regulatory Affairs consulting to support the NIH HEAL [Help End Addiction Long term] PTDP [Pain Therapeutics Development Program]. • Other NIH neuroscience-focused drug discovery and development programs.